1
|
Tan EH, Szczesna A, Krzakowski M, Macha HN, Gatzemeier U, Mattson K, Wernli M, Reiterer P, Hui R, Pawel JV, Bertetto O, Pouget JC, Burillon JP, Parlier Y, Abratt R. Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 2005; 49:233-40. [PMID: 16022917 DOI: 10.1016/j.lungcan.2005.03.029] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2004] [Revised: 03/02/2005] [Accepted: 03/07/2005] [Indexed: 11/27/2022]
Abstract
PURPOSE The objective of this trial was to compare two vinorelbine-based doublets with carboplatin (CBDCA-VC) or with gemcitabine (VG) in patients with stage IIIB-IV non-small cell lung cancer (NSCLC). PATIENTS AND METHODS A total of 316 patients with advanced NSCLC previously untreated were randomized to either vinorelbine 30 mg/m(2) D1,8 with carboplatin AUC 5 D1 (VC) or vinorelbine 25mg/m(2) with gemcitabine (VG) 1000 mg/m(2) both given D1,8 every 3 weeks. The primary endpoint was response rate with secondary parameters being survival (OS), progression-free survival (PFS), tolerance and clinical benefit. RESULTS The median number of cycles was four in each arm with a total of 1268 cycles. The objective response (OR) on intent-to-treat was 20.8% in VC and 28% in VG (p=0.15). Median PFS was 3.9 months in VC and 4.4 months (mo) in VG (p=0.18). Median survival was significantly longer (p=0.01) for VG with 11.5 mo compared to 8.6 mo in VC with 1 year survival at 48.9 and 34.4%, respectively. Tolerance was better in the VG arm as compared to the VC patients. Four toxic deaths were recorded in the VC group. Clinical benefit response rate was 32.4% compared to 40.9% in 111 and 110 evaluable patients in VC and VG, respectively. CONCLUSION VG compared to VC resulted in a similar overall response rate, favourable median survival and a better toxicity profile. For non-cisplatin-based chemotherapy, VG is a useful alternative.
Collapse
Affiliation(s)
- E H Tan
- National Cancer Centre, 11 Hospital Drive, Singapore 169610, Singapore
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Junker K, Müller KM, Linder A, Macha HN, Thomas M. Prognostische Relevanz einer kompletten therapieinduzierten Tumorregression bei lokal fortgeschrittenem neoadjuvant behandelten NSCLC? Pneumologie 2005. [DOI: 10.1055/s-2005-864315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
3
|
Thomas M, Macha HN, Ukena D, Hamm M, Deppermann M, Semik M, Riesenbeck D, Rübe C, Heinecke A. Cisplatin / etoposide (PE) followed by twice-daily chemoradiation (hfRT/CT) versus PE alone before surgery in stage III non-small cell lung cancer (NSCLC): A randomized phase III trial of the German Lung Cancer Cooperative Group (GLCCG). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. Thomas
- Universitätsklinikum, Münster, Germany; Lungenklinik, Hemer, Germany; Universitätsklinikum, Homburg, Germany; Kreiskrankenhaus, Diekholzen, Germany; FLT, Berlin-Buch, Germany
| | - H. N. Macha
- Universitätsklinikum, Münster, Germany; Lungenklinik, Hemer, Germany; Universitätsklinikum, Homburg, Germany; Kreiskrankenhaus, Diekholzen, Germany; FLT, Berlin-Buch, Germany
| | - D. Ukena
- Universitätsklinikum, Münster, Germany; Lungenklinik, Hemer, Germany; Universitätsklinikum, Homburg, Germany; Kreiskrankenhaus, Diekholzen, Germany; FLT, Berlin-Buch, Germany
| | - M. Hamm
- Universitätsklinikum, Münster, Germany; Lungenklinik, Hemer, Germany; Universitätsklinikum, Homburg, Germany; Kreiskrankenhaus, Diekholzen, Germany; FLT, Berlin-Buch, Germany
| | - M. Deppermann
- Universitätsklinikum, Münster, Germany; Lungenklinik, Hemer, Germany; Universitätsklinikum, Homburg, Germany; Kreiskrankenhaus, Diekholzen, Germany; FLT, Berlin-Buch, Germany
| | - M. Semik
- Universitätsklinikum, Münster, Germany; Lungenklinik, Hemer, Germany; Universitätsklinikum, Homburg, Germany; Kreiskrankenhaus, Diekholzen, Germany; FLT, Berlin-Buch, Germany
| | - D. Riesenbeck
- Universitätsklinikum, Münster, Germany; Lungenklinik, Hemer, Germany; Universitätsklinikum, Homburg, Germany; Kreiskrankenhaus, Diekholzen, Germany; FLT, Berlin-Buch, Germany
| | - C. Rübe
- Universitätsklinikum, Münster, Germany; Lungenklinik, Hemer, Germany; Universitätsklinikum, Homburg, Germany; Kreiskrankenhaus, Diekholzen, Germany; FLT, Berlin-Buch, Germany
| | - A. Heinecke
- Universitätsklinikum, Münster, Germany; Lungenklinik, Hemer, Germany; Universitätsklinikum, Homburg, Germany; Kreiskrankenhaus, Diekholzen, Germany; FLT, Berlin-Buch, Germany
| |
Collapse
|
4
|
Abstract
Hemoptysis is a potentially life-threatening complication of various diseases. The most common causes are infectious and inflammatory processes, followed by neoplasms, pulmonary embolisms, mitral stenoses, coagulopathies, and multiple systemic disorders. Primary examinations include a chest x-ray, an angio CT and a bronchoscopy. Sometimes, a bronchial artery angiogram is required. The patient is at risk of suffocation because blood and clots can severely obstruct his airways. Thus, the most important measures are: supplemental oxygen, positioning the patient with the bleeding side down, bronchoscopical suctioning and removal of blood and clots. Coagulopathies have to be corrected. Application of vasoactive drugs may help temporarily. In cases of bleeding from central lesions, coagulation with laser or argon-plasma-coagulator is feasible. Heavy bleeding from the periphery requires a balloon or tube tamponade. Depending on the cause and the severity of the bleeding either anti-inflammatory medical treatment, hemostyptic radiation therapy, bronchial artery embolisation or a surgical procedure must follow.
Collapse
|
5
|
Westhoff M, Kestermann O, Litterst P, Macha HN. Bronchozentrische Granulomatose – Seltene Ursache pulmonaler Rundherde. Pneumologie 2004. [DOI: 10.1055/s-2004-819531] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
6
|
Westhoff M, Reichle G, Macha HN. Churg-Strauss Syndrom – kardiale Beteiligung mit linksatrialem Thrombus. Pneumologie 2004. [DOI: 10.1055/s-2004-819530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
7
|
Junker K, Albrecht N, Linder A, Macha HN, Müller KM, Thomas M. Qualitativ und quantitativ unterschiedliche therapieinduzierte Tumorregression in nicht kleinzelligen Lungenkarzinomen und ihren Lymphknotenmetastasen? Pneumologie 2004. [DOI: 10.1055/s-2004-819552] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
8
|
Albrecht N, Thomas M, Linder A, Macha HN, Müller KM, Junker K. Therapieinduzierte Tumorregression in primären Lungentumoren und ihren Lymphknotenmetastasen. Pneumologie 2003. [DOI: 10.1055/s-2003-815331] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
9
|
Albrecht N, Thomas M, Linder A, Macha HN, Müller KM, Junker K. Therapieinduzierte Tumorregression in primären Lungentumoren und ihren Lymphknotenmetastasen. Pneumologie 2003. [DOI: 10.1055/s-2003-822436] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
10
|
Abstract
Bronchial carcinoma still has a dark prognosis and therapeutic progress remains painfully slow: the 5-year survival rate raised in the last 20 years from 11 to 15%. There are no early symptoms by the tumor and detection by screening is not effective. Worldwide incidence is raising, the falling rates in men in the western world have been compensated by a steep increase in eastern Europe an Asia. Cigarette smoking is in 85% the main cause of this epidemic. Better understanding of genetic predisposition may identify patients at higher risk. Tumor in stage IA-IIB of non small cell carcinoma could gain by neoadjuvant chemotherapy, what is more probable for stage IIA and IIIB. Radiation therapy in combination with chemotherapy improves survival in inoperable stage IIIB. In stage IV disease palliative chemotherapy is superior to best supportive care.
Collapse
MESH Headings
- Biopsy
- Carcinoma, Bronchogenic/diagnosis
- Carcinoma, Bronchogenic/mortality
- Carcinoma, Bronchogenic/pathology
- Carcinoma, Bronchogenic/therapy
- Carcinoma, Non-Small-Cell Lung/diagnosis
- Carcinoma, Non-Small-Cell Lung/mortality
- Carcinoma, Non-Small-Cell Lung/pathology
- Carcinoma, Non-Small-Cell Lung/therapy
- Carcinoma, Small Cell/diagnosis
- Carcinoma, Small Cell/mortality
- Carcinoma, Small Cell/pathology
- Carcinoma, Small Cell/therapy
- Combined Modality Therapy
- Diagnostic Imaging
- Disease-Free Survival
- Early Diagnosis
- Germany/epidemiology
- Humans
- Lung/pathology
- Lung Neoplasms/diagnosis
- Lung Neoplasms/mortality
- Lung Neoplasms/pathology
- Lung Neoplasms/therapy
- Neoplasm Staging
- Smoking/adverse effects
Collapse
Affiliation(s)
- H N Macha
- Pneumologische Abteilung, Lungenklinik Hemer.
| |
Collapse
|
11
|
Rosell R, Gatzemeier U, Betticher DC, Keppler U, Macha HN, Pirker R, Berthet P, Breau JL, Lianes P, Nicholson M, Ardizzoni A, Chemaissani A, Bogaerts J, Gallant G. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 2002; 13:1539-49. [PMID: 12377641 DOI: 10.1093/annonc/mdf332] [Citation(s) in RCA: 241] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND The combination of paclitaxel with cisplatin or carboplatin has significant activity in non-small-cell lung cancer (NSCLC). This phase III study of chemotherapy-naïve advanced NSCLC patients was designed to assess whether response rate in patients receiving a paclitaxel/carboplatin combination was similar to that in patients receiving a paclitaxel/cisplatin combination. Paclitaxel was given at a dose of 200 mg/m(2) (3-h intravenous infusion) followed by either carboplatin at an AUC of 6 or cisplatin at a dose of 80 mg/m(2), all repeated every 3 weeks. Survival, toxicity and quality of life were also compared. PATIENTS AND METHODS Patients were randomised to receive one of the two combinations, stratified according to centre, performance status, disease stage and histology. The primary analyses of response rate and survival were carried out on response-evaluable patients. Survival was also analysed for all randomised patients. Toxicity analyses were carried out on all treated patients. RESULTS A total of 618 patients were randomised. The two treatment arms were well balanced with regard to gender (83% male), age (median 58 years), performance status (83% ECOG 0-1), stage (68% IV, 32% IIIB) and histology (38% squamous cell carcinoma). In the paclitaxel/carboplatin arm, 306 patients received a total of 1311 courses (median four courses, range 1-10 courses) while in the paclitaxel/cisplatin arm, 302 patients received a total of 1321 courses (median four courses, range 1-10 courses). In only 76% of courses, carboplatin was administered as planned at an AUC of 6, while in 96% of courses, cisplatin was given at the planned dose of 80 mg/m(2). The response rate was 25% (70 of 279) in the paclitaxel/carboplatin arm and 28% (80 of 284) in the paclitaxel/cisplatin arm (P = 0.45). Responses were reviewed by an independent radiological committee. For all randomised patients, median survival was 8.5 months in the paclitaxel/carboplatin arm and 9.8 months in the paclitaxel/cisplatin arm [hazard ratio 1.20, 90% confidence interval (CI) 1.03-1.40]; the 1-year survival rates were 33% and 38%, respectively. On the same dataset, a survival update after 22 months of additional follow-up yielded a median survival of 8.2 months in the paclitaxel/carboplatin arm and 9.8 months in the paclitaxel/cisplatin arm (hazard ratio 1.22, 90% CI 1.06-1.40; P = 0.019); the 2-year survival rates were 9% and 15%, respectively. Excluding neutropenia and thrombocytopenia, which were more frequent in the paclitaxel/carboplatin arm, and nausea/vomiting and nephrotoxicity, which were more frequent in the paclitaxel/cisplatin arm, the rate of severe toxicities was generally low and comparable between the two arms. Overall quality of life (EORTC QLQ-C30 and LC-13) was also similar between the two arms. CONCLUSIONS This is the first trial comparing carboplatin and cisplatin in the treatment of advanced NSCLC. Although paclitaxel/carboplatin yielded a similar response rate, the significantly longer median survival obtained with paclitaxel/cisplatin indicates that cisplatin-based chemotherapy should be the first treatment option.
Collapse
Affiliation(s)
- R Rosell
- Hospital Germans Trias i Pujol Hospital, Badalona, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Bolliger CT, Mathur PN, Beamis JF, Becker HD, Cavaliere S, Colt H, Diaz-Jimenez JP, Dumon JF, Edell E, Kovitz KL, Macha HN, Mehta AC, Marel M, Noppen M, Strausz J, Sutedja TG. ERS/ATS statement on interventional pulmonology. European Respiratory Society/American Thoracic Society. Eur Respir J 2002; 19:356-73. [PMID: 11866017 DOI: 10.1183/09031936.02.00204602] [Citation(s) in RCA: 229] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Affiliation(s)
- C T Bolliger
- Medical Faculty, University of Stellenbosch, Tygerberg, South Africa.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Reichle G, Freitag L, Kullmann HJ, Prenzel R, Macha HN, Farin G. [Argon plasma coagulation in bronchology: a new method--alternative or complementary?]. Pneumologie 2000; 54:508-16. [PMID: 11132548 DOI: 10.1055/s-2000-8254] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
Abstract
Argon plasma coagulation (APC) is a thermal coagulation technique that uses ionized argon to transmit high-frequency electrical current, contact free, to tissue. APC has been used in surgery for more than 20 years, particularly for the hemostasis of superficial bleeding. Although APC has become well established in gastrointestinal endoscopy since its introduction in 1991, very few reports of its use in bronchoscopy exist to date. From June 1994 to June 1998, 364 patients (80 women, 284 men), 88% with a confirmed malignant tumor, were treated prospectively in a total of 482 sessions. The single most common indication was recanalization of malignant airway stenoses (186 patients). The defined therapy objective was achieved with good results in 67% of patients. More than 90% of interventions were performed with rigid bronchoscopy. Despite less penetration compared with Nd:YAG laser, extensive bronchial tumors were treatable, in which coagulated tumor fractions were removed either with forceps or bronchoscope tip. The second indication was bleeding in the central airways (119 patients). Acute hemostasis was achieved in 118 patients, 20% in whom the flexible technique under local anesthesia was used. In 34 patients, APC was successfully used to recanalize occluded stents. Rare indications included benign endobronchial tumor, fistula conditioning before fibrin adhesion, and the treatment of scar tissue stenosis. Summarizing all complications, a rate of 3.7% "per treatment" was recorded. Two patients died within 24 hours; their deaths were not directly related to APC. APC is an effective and safe technique for the treatment of bronchologic tumor ablation and hemostasis and can be used with local anaesthetic with flexible bronchoscopy or rigid bronchoscopy with general anesthesia. Compared with Nd:YAG laser, APC is an economic alternative technique offering more effective hemostasis. Furthermore, APC is of particular value as a compliment to well-known techniques, increasing the options in interventional bronchoscopy.
Collapse
Affiliation(s)
- G Reichle
- Lungenklinik Hemer, Pneumologische Abteilung, Hemer.
| | | | | | | | | | | |
Collapse
|
14
|
Thomas M, Rübe C, Semik M, von Eiff M, Freitag L, Macha HN, Wagner W, Klinke F, Scheld HH, Willich N, Berdel WE, Junker K. Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small-cell lung cancer. J Clin Oncol 1999; 17:1185. [PMID: 10561177 DOI: 10.1200/jco.1999.17.4.1185] [Citation(s) in RCA: 107] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE The objective of this prospective study was to assess the feasibility, toxicity, and efficacy of an intensive trimodality approach in stage III non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS Fifty-four patients with NSCLC and biopsy-proven N2 nodes (IIIA; n = 25) or N3 nodes or T4 lesions (IIIB; n = 29) were administered two initial cycles of ifosfamide, carboplatin, and etoposide; subsequent radiotherapy (45 Gy, twice-daily 1.5 Gy) with concurrent carboplatin and vindesine; and surgery if the patient's disease was resectable or conventional radiotherapy (16 Gy, 2 Gy/d) if the patient's disease was not resectable or incompletely resectable. RESULTS Thirty-seven patients (69%) responded to preoperative induction. Forty of 54 patients (74%) had disease that was resectable, with 34 (63%) complete resections (R0). A substantial pathologic response (tumor regression [TR] > 90%) was achieved in 27 of 54 patients (50%) and is revealed as an independent predictor for long-term survival after surgery. Five treatment-related deaths (9%) occurred. With a median follow-up period of 44 months, calculated survival rates at 3 years were 35% for patients with stage IIIA disease, 26% for patients with stage IIIB disease, and 56% for patients with R0 disease and TR > 90%. CONCLUSION This trimodality approach is feasible and results in encouraging 3-year survival rates in prognostically unfavorable patients with stage III NSCLC. Patients experiencing a 90% degree of pathologic TR were most likely to achieve long-term survival.
Collapse
Affiliation(s)
- M Thomas
- Department of Hematology/Oncology and Respiratory Medicine, Westfälische-Wilhelms Universität, Muenster, Germany.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Thomas M, Rübe C, Semik M, von Eiff M, Klinke F, Macha HN, Freitag L, Scheld HH, Willich N, Berdel WE, Junker K. Trimodality therapy in stage III non-small cell lung cancer: prediction of recurrence by assessment of p185neu. Eur Respir J 1999; 13:424-9. [PMID: 10065692 DOI: 10.1183/09031936.99.13242499] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
In a trimodality treatment approach for stage III non-small cell lung cancer the prognostic impact of pretherapeutic p185neu assessment was evaluated. Fifty-four patients were admitted to chemotherapy followed by twice-daily radiation with concomittant low-dose chemotherapy and subsequent surgery. Immunohistochemical assessment of p185neu expression was performed in paraffin-embedded mediastinal lymph node metastases, by mediastinoscopy biopsy prior to therapy. Paraffin-embedded biopsies of mediastinal lymph node metastases were available in 33 cases. Seven out of eight patients with positive p185neu staining developed distant metastases, in contrast to seven out of 25 negative cases. Expression of p185neu in mediastinal lymph node metastases was a significant predictor for progression-free survival (p=0.047) and resulted mainly from significant differences in metastases-free survival (p185neu-positive versus p185neu-negative: median, 11 versus 19 months; 2- and 3-yr rates, 13% and 0% versus 40% and 32%; p=0.04). On the basis of these preliminary results it was concluded that further evaluation of p185neu expression in trials on neoadjuvant and adjuvant therapy is warranted. When the prognostic impact of p185neu in such trials with larger patient numbers is confirmed, this may contribute to the identification of stratification variables for future treatment approaches of non-small cell lung cancer.
Collapse
Affiliation(s)
- M Thomas
- Dept of Hematology/Oncology, Westfälische-Wilhelms Universität, Münster, Germany
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Freitag L, Korupp A, Itzigehl I, Dankwart F, Tekolf E, Reichle G, Kullmann HJ, Macha HN. [Experiences with fluorescence diagnosis and photodynamic therapy in a multimodality therapy concept of operated, recurrent bronchial carcinoma]. Pneumologie 1996; 50:693-9. [PMID: 9019749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Even of those few patients who are operated because of bronchial cancer up to a quarter develop a recurrence. One reason is certainly that tumor-cells already present at the time of surgery are bronchoscopically invisible. Fluorescence methods might be able to detect these malignant cells. For patients with post-surgical recurrences the therapeutical choices are limited due to the loss of parenchyma. Photodynamic therapy (PDT) with the hematoporphyrine derivative Photofrin is one laborious but promising option. Based on an argon-dye laser we have developed a combined system for the diagnostical measurement of autofluorescence and Photofrin-induced fluorescence at 488 nm and the therapeutical PDT at 630 nm. Under the excitation with blue light from the argon laser, differences in the autofluorescence of malignant and benign cells can be distinguished. Following the injection of Photofrin a spectrum peak at 628 nm clearly delineates tumor cells. In six out of twelve patients with post-surgical recurrences a single PDT course resulted in tumor eradication. With additional PDT courses and brachytherapies local tumor control could be achieved in all cases. The general photosensitivity and the necessary light protection were tolerated by all patients. In order to avoid severer complications such as asphyxia, obstruction of bronchi and pneumotharaces resulting from fibrin-plugs and necrotic tissue following PDT must be considered. Especially in patients with pneumonectomy a careful surveillance and debridement is mandatory.
Collapse
|
17
|
Macha HN, Freitag L. The role of brachytherapy in the treatment and control of central bronchial carcinoma. Monaldi Arch Chest Dis 1996; 51:325-8. [PMID: 8909019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
Endobronchial brachytherapy is by far the oldest interventional bronchiological treatment procedure. In the decades following its inception in 1922, it has undergone progressive modification by innovations in radiation physics and techniques, and has enjoyed a renaissance with the introduction of fibreoptic bronchoscopy, local anaesthesia, modern afterloading devices, and high dose rate (HDR) treatment with iridium-192, an isotope with very high activity. However, there is little standardization of dose-specification, fractionation and optimal dosage using this isotope, and homogeneous, objective analyses of the clinical results of treatment using iridium-192 is lacking. Very often, the exact staging of patients is lacking. For such reasons, any evaluation of the efficacy of endobronchial brachytherapy is significantly impeded. However, reliable data are available on the palliative effect of HDR-brachytherapy, which is safe, fast in onset and apparently superior to external beam radiotherapy (EBRT) alone. In addition, some studies document the curative effects, or complications, offers not only an insight into the working principles of radiation treatment but also into the biological behaviour of bronchial tumours. Endobronchial HDR-brachytherapy should be compared to the other interventional procedures focusing on the same aim, namely that of restoring patency of a previously occluded bronchus. This is the overall challenge to pneumologists working in this field.
Collapse
Affiliation(s)
- H N Macha
- Lungenklinik Hemer, Pneumolog, Abteilung, Hemer, Germany
| | | |
Collapse
|
18
|
Achatzy R, Kelm C, Kutzner K, Macha HN. [Lung surgery in elderly patients, a retrospective study (1985-1994)]. Langenbecks Arch Chir Suppl Kongressbd 1996; 113:828-9. [PMID: 9101999] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
From 1985 to 1994, we performed 4568 thoracic operations, 234 of these patients (176 males, 58 females) were older than 70 years of age; the oldest patient was 82 years. Of these 234 patients, 144 suffered from bronchial carcinornas, 25 from lung metastases, 21 from recurrent pneumothoraces, 12 from thymomas, 21 from tuberculomas, hamartomas, an intrathoracic goiter or mesothelioma; in 11 patients, diagnostic thoracotomias or biopsies had been done. We did 146 anatomical resections, 59 atypical wedge resections, 14 decortications, pleurectomies, thymectomies or exstirpations of mediastinal tumors; in addition, three resections of an intrathoracic goiter were done. The hospital lethality was 3.8%, the total rate of complications 56%, mostly cardiac arrhythmias. The survival rate of the patients suffering from a bronchial carcinoma was the same as in younger patients.
Collapse
|
19
|
Thomas M, Macha HN, Rübe C, van de Loo J. [Value of chemotherapy in multi-modal treatment of non-small-cell bronchial carcinoma]. Dtsch Med Wochenschr 1995; 120:1627-30. [PMID: 7493564 DOI: 10.1055/s-2008-1055522] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Affiliation(s)
- M Thomas
- Medizinische Klinik und Poliklinika, Universität Münster
| | | | | | | |
Collapse
|
20
|
Macha HN, Wahlers B, Reichle C, von Zwehl D. Endobronchial radiation therapy for obstructing malignancies: ten years' experience with iridium-192 high-dose radiation brachytherapy afterloading technique in 365 patients. Lung 1995; 173:271-80. [PMID: 7564485 DOI: 10.1007/bf00176890] [Citation(s) in RCA: 50] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
From 1983 to 1993, 365 patients with obstructing endobronchial malignancies were treated by endobronchial high-dose radiation (HDR) iridium-192 afterloading. In 346 patients, the objective was palliation, and in 19, the objective was curative. A dose of 5 Gy at 10 mm from the source axis was administered on three (palliation) and four (cure) occasions, at intervals of 14 days. The majority of patients were treated after exhaustion of external beam radiation therapy (EBRT), often in conjunction with other interventional bronchologic modalities such as endobronchial laser resection. Of the patients, 65% had a squamous cell carcinoma. Endobronchial HDR brachytherapy results in few acute complications and can be performed with no major discomfort on an outpatient basis. In approximately 66% of patients, a palliative effect is achieved, even after the exhaustion of conventional treatment. Life may be prolonged for a few months, but the enhancement of survival is difficult to assess for several reasons. Mean survival is 9 months for limited disease and 5 months for extensive disease. Endobronchial HDR brachytherapy influences the pattern of failure: a 21% rate of fatal hemorrhages is probably the result of the selection of patients for this treatment rather than a treatment-related complication. There is sufficient evidence to suggest the rational use of HDR brachytherapy in combination with EBRT to effect a cure, or even on its own when tumor growth is strictly limited. However, the standardization of radiotherapy and endoscopic indications is an urgent priority. Prospective, controlled, and cooperative studies are mandatory. Endobronchial iridium-192 HDR brachytherapy complements endobronchial laser resection and is currently an established technique in the treatment of advanced malignant airway obstruction.
Collapse
Affiliation(s)
- H N Macha
- Department of Chest Diseases, Lungenklinik, Hemer, Germany
| | | | | | | |
Collapse
|
21
|
Orth M, Achatzy R, Macha HN, Müller KM, Wiebe V, Schultze-Werninghaus G. [Pleuro-mediastinitis in pulmonary actinomycosis as a rare differential bronchial carcinoma diagnosis]. Pneumologie 1995; 49:505-8. [PMID: 8532645] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
A 48-year old patient complaining of immitigable coughing with purulent and sanguineous sputum and a loss of weight of 8 kg within the last three months was admitted to our hospital. Due to anamnesis and radiological findings (tumor of the right side upper lung field with infiltration of the chest wall and the mediastinum) we suspected a bronchogenic carcinoma. As bronchoscopy and histological examinations of biopsies revealed no hints to the underlying disease, we submitted the patient to a right side explorative thoracotomy. It showed a tumorous involvement of the right side upper lung field with infiltration and partial destruction of the chest wall and infiltration of the apical segment of the lower lobe of the lung and a phlegmonous infiltration of the paratracheal tissue. Histological examination confirmed chronical course of actinomycosis. Therapy consisted in resection of the affected tissue and long-term administration of antibiotics. Response to therapy was excellent concerning both radiological findings and subjective complaints.
Collapse
Affiliation(s)
- M Orth
- Berufsgenossenschaftliche Kliniken Bergmannsheil, Universitätsklinik/Ruhr-Universität Bochum
| | | | | | | | | | | |
Collapse
|
22
|
Abstract
To evaluate the influence of endobronchial laser resection on survival and the pattern of failure in patients with bronchial malignancies, we investigated 75 patients prospectively. These patients had radiation therapy (mean external dose, 53.1 Gy) and endobronchial laser resection to treat an inoperable or recurrent bronchial carcinoma occluding a major airway. Complete recanalization was achieved in 36 percent, partial recanalization was achieved in 51 percent, and no recanalization was achieved in 13 percent. These 75 patients were matched retrospectively with a group of 75 patients who received external radiation therapy because of the same indications, but because of endobronchial compression of a major airway by the tumor, received no laser resection. The patients were matched for age, sex, TNM-status, histologic features, external radiation dose and fractionation, lung resection, cytotoxic therapy, and brachytherapy; they were treated in the same period. The incidence of terminal hemorrhage was four times higher in patients who received endobronchial laser resection (34.5 percent) compared with those who did not (7.7 percent). Successful laser reopening of a major airway influenced the pattern of failure: with full recanalization the cause of death in 23.3 percent of cases was respiratory failure and in 26.7 percent, terminal hemorrhage; whereas with no recanalization these figures were 56.3 percent and 18.8 percent, respectively. Laser resection did not influence overall survival, but in patients with full reopening of a bronchus, the time interval from treatment to death was prolonged by more than 4 months compared with those patients in whom recanalization failed. Comparing our observations on the immediate cause of death with reports in the literature, we conclude that the higher percentage of terminal hemorrhage in patients receiving endobronchial laser resection is not directly related to the treatment, but reflects different patterns of tumor growth with respect to mucosal destruction not covered by the TNM system.
Collapse
Affiliation(s)
- H N Macha
- Department of Pneumology, Lungenklinik, Hemer, Germany
| | | | | |
Collapse
|
23
|
|
24
|
Macha HN, Reichle G, von Zwehl D, Kemmer HP, Bas R, Morgan JA. The role of ultrasound assisted thoracoscopy in the diagnosis of pleural disease. Clinical experience in 687 cases. Eur J Cardiothorac Surg 1993; 7:19-22. [PMID: 8431297 DOI: 10.1016/1010-7940(93)90142-x] [Citation(s) in RCA: 27] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
Ultrasonic examination is an established method used to differentiate between solid and liquid structures in the pleural space. It can estimate the volume of a pleural effusion and demonstrate whether the effusion is associated with loculations or adhesions. It is complementary to thoracoscopy. In the diagnosis of pleural disease ultrasonic-assisted thoracoscopy should only be used when the less invasive methods of diagnosis such as pleural aspiration for cytological, bacteriological and chemical examinations and needle biopsy of the pleura have not yielded a diagnosis. Although thoracoscopy is a relatively invasive procedure, it has the advantages of speed and accuracy in the diagnosis of pleural disease. This procedure is not widely used as it requires specialized instruments and equipment and may be time-consuming. The latter disadvantage may be minimized by the use of prior pleural sonography. The ultrasonic examination will indicate the optimal point of entry of the thoracoscopy to avoid adhesions. In order to evaluate feasibility, complications and clinical results in ultrasonic-assisted thoracoscopy, we investigated 687 patients with pleural diseases from 1987 to 1990. As prior induction of a pneumothorax under X-ray control was not necessary, the 20-30 min required for this procedure was saved in all patients. Very few complications were attributable to ultrasonic-assisted thoracoscopy as it could normally be performed under local anesthesia. A macroscopic diagnosis was made in 80% of malignant diseases and 77% of inflammatory diseases in our total of 687 thoracoscopies. The diagnosis of a malignant pleural effusion was confirmed histologically and cytologically in 95% of those 190 patients in whom it was present.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- H N Macha
- Pneumologische Abteilung, Lungenklinik Hemer, FRG
| | | | | | | | | | | |
Collapse
|
25
|
Macha HN. [Bronchial carcinoma: how far should the diagnosis go?]. Pneumologie 1991; 45:508-10. [PMID: 1924226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Affiliation(s)
- H N Macha
- Pneumologische Abteilung, Lungenklinik Hemer
| |
Collapse
|
26
|
Macha HN, Wahlers B. [Endobronchial brachytherapy: endoluminal small-volume irradiation of bronchial tumors using the high-dose-rate afterloading method]. Pneumologie 1991; 45:95-9. [PMID: 1709501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Endobronchial irradiation has been in use for over 70 years. This method of treatment has become much less of a burden to the patient thanks to developments in isotope technology, bronchoscopy and radiation therapy. It is effective in providing good palliation and in central bronchial tumours with involvement of the large airways, endobronchial irradiation has proved to be a valuable addition to our armamentarium. In the context of curative irradiation it may be combined with external beam irradiation. In tumours confined to the bronchial wall, endobronchial irradiation alone has been successfully used to achieve a cure. This method should however only be used in large thoracic centres as there are relatively few indications for its use.
Collapse
Affiliation(s)
- H N Macha
- Pneumologische und Radiologische Abteilung, Lungenklinik Hemer
| | | |
Collapse
|
27
|
Halm H, Achatzy R, Macha HN, Wahlers B. [Thrombosis of the left jugular-subclavian vein junction as a rare late complication of oleothorax]. Pneumologie 1990; 44:1264-6. [PMID: 2281078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Thirty years after bilateral pneumolysis followed by plombage with paraffin for bilateral upper lobe tuberculosis, a 58-year-old female patient suffered a thrombosis of the left jugular- subclavian vein junction. Compression of the vessel by the plombage in addition to chronic fibrous scar tissue reaction must be assumed as the main cause of thrombosis, since infection of the plombage space was excluded.
Collapse
Affiliation(s)
- H Halm
- Abteilung für Thorax- und Gefässchirurgie, Lungenklinik Hemer, Zentrum für Pneumologie, Thorax- und Gefässchirurgie
| | | | | | | |
Collapse
|
28
|
Vestring T, Achatzy R, Wahlers B, Macha HN, Peters PE. [Mediastinal staging of non-small cell bronchial carcinoma. The place of computed tomography and mediastinoscopy]. Radiologe 1990; 30:178-84. [PMID: 2160672] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Sixty patients with a potentially resectable non-oat-cell lung carcinoma were examined by computed tomography and cervical mediastinoscopy. The sensitivity of computed tomography as opposed to mediastinoscopy was 74% versus 58% and the specificity in 85% versus 100%. Considering the limitations of both methods and the varying prevalence of mediastinal lymph-node metastases associated with peripheral and central lesions, three different situations can be distinguished: 1. with peripheral lesions and a normal mediastinal CT, preoperative mediastinoscopy is unnecessary. 2. With an abnormal mediastinal CT, mediastinoscopy is always indicated irrespective of the location of the tumor. 3. With large central lesions, mediastinoscopy is necessary even when the CT is normal. Using these rules, 37 of 60 mediastinoscopies in our patient group could have been avoided without influencing the resection rate (98%).
Collapse
Affiliation(s)
- T Vestring
- Institut für Klinische Radiologie, Universitätsklinik Münster
| | | | | | | | | |
Collapse
|
29
|
Achatzy R, Beba W, Ritschler R, Wörn H, Wahlers B, Macha HN, Morgan JA. The diagnosis, therapy and prognosis of diffuse malignant mesothelioma. Eur J Cardiothorac Surg 1989; 3:445-7; discussion 448. [PMID: 2635926 DOI: 10.1016/1010-7940(89)90056-0] [Citation(s) in RCA: 46] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
Between 1969 and 1985, 245 patients with diffuse malignant mesothelioma were treated (157 male, 88 female). The average age was 55.8 years and the sex ratio was 1.8:1 in favour of males. The right side was more frequently affected than the left (56.7% vs. 43.3%). A pleural effusion and dyspnoea were the presenting signs and symptoms in 83.7% of the patients and unilateral chest pain in 64.2%. Noninvasive diagnostic procedures included a chest X-ray and computed tomography of the thorax. Pleural effusion and pleural thickening were detected most frequently. Malignant cells were identified by pleural fluid cytology in 45.3% and by needle biopsy of the pleura in 42.7% of the patients. Forty-five patients were treated conservatively and 200 patients underwent operation: diagnostic thoracotomy (78); partial pleurectomy (72); total pleurectomy (46); extended pleuropneumonectomy (2); partial removal of the diaphragm (1) and total pleurectomy and upper lobectomy (1). The perioperative mortality was 6%. The conservative and postoperative treatment depended on the patients' symptoms and included radiotherapy and chemotherapy alone or in combination. The mean survival time of the 222 non-survivors was 9.2 months. After 1 year, 36% of the patients were still alive, after 2 years, 10.8% and the 5-year survival was 4.1%. The median survival time in patients treated non-operatively was 6 months--a little over half that of the patients treated surgically (10.1 months).
Collapse
Affiliation(s)
- R Achatzy
- Department of Pneumonology, Lungenklinik Hemer, Federal Republic of Germany
| | | | | | | | | | | | | |
Collapse
|
30
|
Macha HN, Koch K, Stadler M, Schumacher W, Krumhaar D. New technique for treating occlusive and stenosing tumours of the trachea and main bronchi: endobronchial irradiation by high dose iridium-192 combined with laser canalisation. Thorax 1987; 42:511-5. [PMID: 2449742 PMCID: PMC460813 DOI: 10.1136/thx.42.7.511] [Citation(s) in RCA: 83] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
A new technique is described for treating patients with inoperable malignant tumours causing occlusion or stenosis of the trachea or main bronchi. High dose iridium-192 (20 Ci) was introduced by an afterloading device under computer control via a 4 mm delivery tube into the tumour mass. In 29 of the 56 patients the tumour mass was canalised by a neodymium-YAG laser immediately before the afterloading delivery tube was introduced. In 44 (79%) of the patients, there was impressive relief of dyspnoea, accompanied by tumour regression observed at endoscopy and also by highly significant improvement in ventilatory function values, lung perfusion scans, and levels of arterial oxygen tension. In the other 12 patients (21%) there was no detectable improvement. The findings suggest that this recently developed combination treatment is of value in patients with advanced tumours of the trachea and main bronchi in whom there is no possibility of further treatment by external irradiation or repeated laser coagulation.
Collapse
Affiliation(s)
- H N Macha
- Department of Chest Diseases, Lungenklinik Hemer, West Germany
| | | | | | | | | |
Collapse
|
31
|
Macha HN, Mai J, Stadler M, Koch K, Loddenkemper R, Krumhaar D, Schumacher W. [New methods in the radiotherapy of bronchial carcinoma. Endobronchial small-field irradiation using the iridium-129 high-dose afterloading technic in combination with the neodymium-YAG laser]. Dtsch Med Wochenschr 1986; 111:687-91. [PMID: 2421994 DOI: 10.1055/s-2008-1068513] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
106 patients with inoperable malignant tumours constricting the central bronchial tree underwent endobronchial small-field radiotherapy with iridium-192 at high dose between June 1983 and September 1985. Treatment was performed using the computer-guided after-loading technique and a flexible bronchoscope under local anaesthesia. In complete occlusion of a bronchus by the tumour, a neodymium YAG-laser was applied (57 patients) to allow insertion of the after-loading probe. Endoscopy showed tumour regression in 75% of the patients, accompanied by clinical improvement. Pulmonary function tests, arterial blood gas analyses and pulmonary perfusion scans yielded a highly significant improvement of data after treatment. The procedure also proved effective upon exhaustion of external radiation. Apart from its positive palliation, endobronchial small-field radiotherapy using high doses of iridium-192 also has a curative effect, thus opening up a new approach to the therapy of advanced bronchial carcinoma.
Collapse
|
32
|
Petro W, Zimmermann W, Loddenkemper R, Macha HN, Konietzko N. [Effect of bronchoscopy (rigid and fiberoptic) on respiratory mechanics and reactivity of the airways]. Prax Klin Pneumol 1983; 37 Suppl 1:866-70. [PMID: 6647358] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|
33
|
|
34
|
Macha HN, Aurich R. Comparative studies of atropine methonitrate and its combination with reproterol in chronic airway obstruction. Arzneimittelforschung 1982; 32:774-776. [PMID: 6751338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
Abstract
The therapeutic value of 80 micrograms atropine methonitrate delivered per metered aerosol and its combination with 450 micrograms reproterol was investigated in a controlled double-blind cross-over trial in 17 patients with chronic bronchitis and airway obstruction. All patients were atropine responders. According to the parameters of FEV1 and SGaw atropine methonitrate induced a statistically definite and clinically relevant bronchodilation for more than 3 h compared with placebo. The combination of 80 micrograms atropine methonitrate and 450 micrograms reproterol, however, proved to be clearly superior compared with the mono-compound atropine methonitrate.
Collapse
|
35
|
Wunderlich J, Macha HN, Wudicke H, Huckauf H. Beta-adrenoceptor blockers and terbutaline in patients with chronic obstructive lung disease. Effects and interaction after oral administration. Chest 1980; 78:714-20. [PMID: 6107217 DOI: 10.1378/chest.78.5.714] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Abstract
We studied the effects of a combined treatment with beta 2-stimulating and beta-blocking drugs in 35 patients suffering from chronic obstructive lung disease (COLD) and ischemic heart disease, and/or arterial hypertension. The drugs used were equipotent repeated oral doses of metoprolol (100 mg twice daily [bid]), propranolol (80 mg bid), and a matching placebo for beta-adrenoceptor blockade given in a double-blind and crossover fashion. The intake period of each beta-blocker was two days with consecutive two-day-washout period; 2.5 mg terbutaline and beta-stimulator placebo, respectively, were given throughout the whole trial three times daily (tid). Propranolol alone caused severe deterioration of lung function. After 18 patients had been studied, this drug had to be excluded from the trial. When compared with placebo, metoprolol provoked increasing obstruction, too, but to a significantly lesser degree than propranolol. These negative effects on FEV1 and FRC were completely equalized by terbutaline. Predictive factors for the tolerability of beta-blockers in patients with COLD could not be found. Therefore, careful observations in the initial phase of the treatment with beta-selective blockers are necessary.
Collapse
|
36
|
Abstract
The acute broncholytic efficacy and the protective anticonstrictive effectiveness of a new beta 2-receptor stimulator, Reproterol, was tested in 16 patients with the acetylcholine (ACH) provocation test. Plethysmographic airway resistance determinations (Raw) and flow volume curves (VEmax50%/FVC) were used as assessment parameters. All patients proved susceptible to ACH provocation, in as much they demonstrated a significant rise in the Raw from 2.46 to 11.53 cm H2O/1/sec and a significant decline of the VEmax50%/FVC from 884 to 565 (ml/sec/1) following ACH administration. With Reproterol inhalation (2 puffs at 500 mu each), almost complete elimination of ACH-induced bronchial constriction was achieved. The ACH provocation with the same patients the following day, however, was almost absent 60 min after oral ingestion of 20 mg of Reproterol tablets. Dose-efficacy studies in 7 volunteers from the same group revealed a subjectively better tolerance of the 10-mg tablets, but with a correspondingly lower antibronchia constrictive efficacy.
Collapse
|
37
|
|
38
|
Schüren KP, Macha HN. [Acute and long term action of isosorbide dinitrate on the pulmonary circulation, right ventricular function and arterial blood gases in patient with chronic cor pulmonale]. Verh Dtsch Ges Inn Med 1977; 83:1687-90. [PMID: 347794] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
39
|
Bungert HJ, Leonhardt H, Macha HN. [Quantitative and qualitative determination of iron in primary and secondary pulmonary haemosiderosis]. Dtsch Med Wochenschr 1972; 97:692-5 passim. [PMID: 5025683 DOI: 10.1055/s-0028-1107424] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
|
40
|
Bungert HJ, Leonhardt H, Macha HN. [Physico-chemical studies on the ferritin and protein spectrum in a case of pulmonary hemosiderosis with glomerulonephritis. (Goodpasture's syndrome)]. Klin Wochenschr 1971; 49:1257-64. [PMID: 5135944 DOI: 10.1007/bf01733078] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|
41
|
Bungert HJ, Leonhardt H, Macha HN. [Immunologic studies of ferritin in a case of pulmonary haemosiderosis and glomerulonephritis (Goodpasture-syndrome)]. Clin Chim Acta 1971; 35:231-6. [PMID: 5001738 DOI: 10.1016/0009-8981(71)90316-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
|
42
|
Treichel J, Macha HN. [Roentgenographic findings of a hydrochlorid acid burn of the stomach and its pathological-anatomical correlation]. Fortschr Geb Rontgenstr Nuklearmed 1971; 115:120-2. [PMID: 5105640] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
|
43
|
Bungert HJ, Leonhardt H, Macha HN. [Starch gel electrophoresis studies of ferritin in a case of pulmonary hemosiderosis and glomerulonephritis]. Clin Chim Acta 1971; 32:385-9. [PMID: 5096952 DOI: 10.1016/0009-8981(71)90439-6] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
|
44
|
Macha HN, Treichel J. [Roentgenological and pathomorphological finding of the stomach after hydrochloric acid burns]. Med Monatsschr 1971; 25:17-20. [PMID: 5546751] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|